UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4590683 ( State or other juri ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Ted Jenkins - VP & Head, IR Ankit Mahadevia - Co-Founder, President, CEO & Director Kamal Hamed - Chief Medical Officer Satyavrat Shukla - CFO & Treasurer Conference Call Participants Louise Chen - Cantor Fitzgerald & Co. Operator Good afternoon, and welcome to Spero Therapeutics Fourth Quarter and Year-End 2022 Financial Results Conference Call. [Operator Instructions]. Please be advised t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____to____ Commission file number 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4590683 State or other juri ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations & Strategic Finance Ankit Mahadevia - Chief Executive Officer Kamal Hamed - Chief Medical Officer Sat Shukla - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Louise Chen - Cantor Ritu Baral - Cowen Operator Good afternoon and welcome to the Spero Therapeutics' Third Quarter 2022 Financial Results C ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President-Investor Relations & Strategic Finance Ankit Mahadevia - Chief Executive Officer David Melnick - Consultant & Senior Clinical Advisor Sath Shukla - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen Louise Chen - Cantor Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon, and welcome to the Spero Therapeutics Second Quarter 2022 ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President-Investor Relations Ankit Mahadevia - Chief Executive Officer David Melnick - Chief Medical Officer Sath Shukla - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Ram Selvaraju - H.C. Wainwright Kevin DeGeeter - Oppenheimer Elaine Kim - Berenberg Operator Good afternoon, and welcome to the Spero Therapeutics First Quarter of 2022 Financial ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2021 Earnings Conference Call March 31, 2022 4:30 PM ET Company Participants Ted Jenkins - VP, Head of IR Ankit Mahadevia - CEO David Melnick - Chief Medical Officer Cristina Larkin - COO Sath Shukla - CFO Conference Call Participants Louise Chen - Cantor Ritu Baral - Cowen Esther Hong - Berenberg Kevin DeGeeter - Oppenheimer Operator Good afternoon, and welcome to the Spero Therapeutics Fourth Quarter and Year-End 2021 Financial Results Conference Call. [Operator I ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Ted Jenkins - Vice President, Head of Investor Relations Ankit Mahadevia - Chief Executive Officer David Melnick - Chief Medical Officer Cristina Larkin - Chief Operating Officer Sath Shukla - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen Louise Chen - Cantor Fitzgerald & Co. Ram Selvaraju - H.C. Wainwright Esther Hong - Berenberg Operator Good afternoon, and we ...

Spero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update August 5, 2021 Tebipenem HBr on track for NDA submission in the fourth quarter of 2021 Announced $40 million equity investment from Pfizer Inc. and licensing agreement for SPR206 Initiated Phase 1 bronchoalveolar lavage and renal impairment clinical trials of SPR206 Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Ted Jenkins - VP, IR Ankit Mahadevia - Co-Founder, CEO, President & Director David Melnick - Chief Medical Officer Cristina Larkin - COO Satyavrat Shukla - CFO Conference Call Participants Lyla Youssef - Cowen and Company Louise Chen - Cantor Fitzgerald & Co. Kevin DeGeeter - Oppenheimer Esther Hong - Berenberg Raghuram Selvaraju - H.C. Wainwright & Co. Operator Good day, everyone, and than ...